辅助卫生从业者远程出院后管理急性心肌梗死患者与标准护理的比较:IMMACULATE随机临床试验
这项在新加坡3家医院进行的意向性治疗可行性随机试验,将301例接受早期血运重建且NT-proBNP>300 pg/mL的急性心肌梗死患者随机分为辅助卫生从业者主导的远程强化管理(RIM)组(149例)和心内科医生主导的标准护理(SC)组(152例)。RIM组接受6个月远程咨询,由中央化执业护士团队调整β受体阻滞剂和ACE-I/ARB剂量;SC组由心内科医生面对面治疗。6个月β受体阻滞剂和ACE-I/ARB剂量强度评分组间差异无统计学意义,6个月 indexed LVESV 亦无显著差异。结论认为,在低危血运重建后心梗患者中,由辅助卫生专业人员实施的RIM可行且安全,但达到的药物剂量或左室重构指标无差异,需在高危人群中进一步研究。
要点
- 在低危心梗血运重建后患者中,护士主导的远程药物调整可行且安全。
- RIM与标准护理在6个月β受体阻滞剂和ACE-I/ARB剂量强度上无显著差异。
- 两组6个月 indexed LVESV 无显著差异,提示左室重构指标相似。
核心结论
- 在血运重建后的低危心梗患者中,由辅助卫生专业人员实施的远程强化管理可行且安全。
- RIM与标准护理在达到的药物剂量或左室重构指标上无差异。
- 需在高危队列中进一步研究RIM。
研究设计与样本
- 意向性治疗可行性随机临床试验,在新加坡3家医院进行,2015年7月8日至2019年3月29日纳入301例接受早期血运重建且NT-proBNP>300 pg/mL的急性心肌梗死患者。
- 149例(49.5%)随机至远程强化管理(RIM)组,152例(50.5%)至标准护理(SC)组。
- RIM组接受6个月远程咨询,由中央化执业护士团队调整β受体阻滞剂和ACE-I/ARB剂量;SC组由心内科医生面对面治疗。
主要发现
- 基线特征:平均(SD)年龄55.3(8.5)vs 54.7(9.1)岁;中位(IQR)NT-proBNP 807(524-1360)vs 819(485-1320)pg/mL;平均(SD)基线LVEF 57.4%(11.1%)vs 58.1%(10.3%);平均(SD)indexed LVESV 32.4(14.1)vs 30.6(11.7)mL/m2;15例(5.9%)LVEF<40%。
关键数值与推荐
- 纳入标准:急性心肌梗死接受早期血运重建且NT-proBNP浓度>300 pg/mL。
- 主要安全终点:因低血压、心动过缓、高钾血症或急性肾损伤住院的复合终点。
- 主要疗效终点:6个月 indexed LVESV(经基线LVESV调整)。
- 剂量强度评分:将不同β受体阻滞剂和ACE-I/ARB的可比剂量转换为0至5分的量表。
临床怎么用
- 对于低危心梗血运重建后患者,可考虑由辅助卫生专业人员(如执业护士)主导的远程管理进行药物剂量调整。
- 远程管理需监测低血压、心动过缓、高钾血症和急性肾损伤等安全事件。
- 该策略在低危人群中未显示优于标准护理的疗效,不应常规替代心内科医生主导的面对面随访。
局限性
- 为可行性试验,样本量301例,可能不足以检测组间差异。
- 研究人群为低危患者(仅5.9% LVEF<40%),结果不能推广至高危心梗患者。
- 试验在新加坡3家医院进行,医疗体系差异可能影响普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are few data on remote postdischarge treatment of patients with acute myocardial infarction. OBJECTIVE: To compare the safety and efficacy of allied health care practitioner-led remote intensive management (RIM) with cardiologist-led standard care (SC). DESIGN, SETTING, AND PARTICIPANTS: This intention-to-treat feasibility trial randomized patients with acute myocardial infarction undergoing early revascularization and with N-terminal-pro-B-type natriuretic peptide concentration more than 300 pg/mL to RIM or SC across 3 hospitals in Singapore from July 8, 2015, to March 29, 2019. RIM participants underwent 6 months of remote consultations that included β-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACE-I/ARB) dose adjustment by a centralized nurse practitioner team while SC participants were treated face-to-face by their cardiologists. MAIN OUTCOMES AND MEASURES: The primary safety end point was a composite of hypotension, bradycardia, hyperkalemia, or acute kidney injury requiring hospitalization. To assess the efficacy of RIM in dose adjustment of β-blockers and ACE-I/ARBs compared with SC, dose intensity scores were derived by converting comparable doses of different β-blockers and ACE-I/ARBs to a scale from 0 to 5. The primary efficacy end point was the 6-month indexed left ventricular end-systolic volume (LVESV) adjusted for baseline LVESV. RESULTS: Of 301 participants, 149 (49.5%) were randomized to RIM and 152 (50.5%) to SC. RIM and SC participants had similar mean (SD) age (55.3 [8.5] vs 54.7 [9.1] years), median (interquartile range) N-terminal-pro-B-type natriuretic peptide concentration (807 [524-1360] vs 819 [485-1320] pg/mL), mean (SD) baseline left ventricular ejection fraction (57.4% [11.1%] vs 58.1% [10.3%]), and mean (SD) indexed LVESV (32.4 [14.1] vs 30.6 [11.7] mL/m2); 15 patients [5.9%] had a left ventricular ejection fraction <40%. The primary safety end point occurred in 0 RIM vs 2 SC participants (1.4%) (P = .50). The mean β-blocker and ACE-I/ARB dose intensity score at 6 months was 3.03 vs 2.91 (adjusted mean difference, 0.12 [95% CI, -0.02 to 0.26; P = .10]) and 2.96 vs 2.77 (adjusted mean difference, 0.19 [95% CI, -0.02 to 0.40; P = .07]), respectively. The 6-month indexed LVESV was 28.9 vs 29.7 mL/m2 (adjusted mean difference, -0.80 mL/m2 [95% CI, -3.20 to 1.60; P = .51]). CONCLUSIONS AND RELEVANCE: Among low-risk patients with revascularization after myocardial infarction, RIM by allied health care professionals was feasible and safe. There were no differences in achieved medication doses or indices of left ventricular remodeling. Further studies of RIM in higher-risk cohorts are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02468349.
引用
- Chan MY, Koh KWL, Poh SC, et al. Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 33377898. doi:10.1001/jamacardio.2020.6721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。